Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial
- PMID: 26417001
- DOI: 10.1200/JCO.2015.60.9719
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial
Abstract
Purpose: To assess the effects of adjuvant hormone therapy (AHT) on survival and disease outcome in women with epithelial ovarian cancer.
Patients and methods: Participants were premenopausal and postmenopausal women who had been diagnosed with epithelial ovarian cancer (any International Federation of Gynecology and Obstetrics stage) 9 or fewer months previously. Ineligible patients included those with deliberately preserved ovarian function, with a history of a hormone-dependent malignancy, or with any contraindications to hormone-replacement therapy. Patients were centrally randomly assigned in a 1:1 ratio to either AHT for 5 years after random assignment or no AHT (control). Main outcome measures were overall survival (OS), defined as time from random assignment to death (any cause), and relapse-free survival, defined as time from random assignment to relapse or death (any cause). Patients who continued, alive and relapse free, were censored at their last known follow-up.
Results: A total of 150 patients (n = 75, AHT; n = 75, control) were randomly assigned from 1990 to 1995 from 19 centers in the United Kingdom, Spain, and Hungary; all patients were included in intention-to-treat analyses. The median follow-up in alive patients is currently 19.1 years. Of the 75 patients with AHT, 53 (71%) have died compared with 68 (91%) of 75 patients in the control group. OS was significantly improved in patients who were receiving AHT (hazard ratio, 0.63; 95% CI, 0.44 to 0.90; P = .011). A similar effect was seen for relapse-free survival (hazard ratio, 0.67; 95% CI, 0.47 to 0.97; P = .032). Effects remained after adjustment for known prognostic factors.
Conclusion: These results show that women who have severe menopausal symptoms after ovarian cancer treatment can safely take hormone-replacement therapy, and this may, in fact, infer benefits in terms of OS in addition to known advantages in terms of quality of life.
© 2015 by American Society of Clinical Oncology.
Comment in
-
To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.J Clin Oncol. 2015 Dec 10;33(35):4127-8. doi: 10.1200/JCO.2015.63.6670. Epub 2015 Oct 5. J Clin Oncol. 2015. PMID: 26438113 Free PMC article. No abstract available.
-
On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer.J Clin Oncol. 2016 Jun 10;34(17):2070-1. doi: 10.1200/JCO.2015.66.3245. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001577 No abstract available.
-
Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis.J Clin Oncol. 2016 Jun 10;34(17):2071-2. doi: 10.1200/JCO.2016.66.7709. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001582 No abstract available.
-
Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?J Clin Oncol. 2016 Jun 10;34(17):2069. doi: 10.1200/JCO.2015.65.3683. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001584 No abstract available.
-
Analysis of the Adjuvant Hormone Therapy Randomized Trial.J Clin Oncol. 2016 Jun 10;34(17):2070. doi: 10.1200/JCO.2015.65.4277. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001585 No abstract available.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical